About
CEVR Team
Careers
Read for the Registry
Contact Us
News & Events
News
Events
Publications
Databases
CEA Registry
GH CEA Registry
SPEC Database
Sponsorship
Sponsor login
Contact Us
News & Events
News
Despite criticisms of Accelerated Approval pathway—commercial payers defer to FDA
By Fariel LaMountain, BA, Molly T. Beinfeld, MPH, and James D. Chambers, PhD, MPharm, MSc March 14, 2024 Introduction Uncertainties in the underlying ...
Join our team: CEVR is Hiring a Post Doctoral Fellow!
Job Overview The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center and argenx are pleased to announce a post-docto...
Join our Team: CEVR is Hiring a Research Assistant!
Job Overview The Research Assistant III will be a member of the Institute for Clinical Research and Health Policy Studies (ICRHPS) at Tufts Medical Ce...
View All News Items
Events
Health Policy Seminar with Robert S. Rudin, PhD
Health Policy Seminar with Edward Cliff, MBBS, MPH
CEVR Webinar with James Chambers - "US Payer Coverage of Specialty Drugs: Outlook for 2024"
View All Events
Publications
Health Affairs Forefront
Are We Valuing Prescription Drugs Appropriately?
Health Policy Open
Variation in Medicaid and commercial coverage of cell and gene therapies
Journal of Alzheimer's Disease
Life-Sustaining Treatments Among Medicare Beneficiaries with and without Dementia at the End of Life
Health Affairs Forefront
The Case For Including Dynamic Drug Pricing In Cost-Effectiveness Analyses Under The IRA
The American Journal of Managed Care
Varied Use of Step Therapy Among Medicare Advantage Plans
The Milbank Quarterly
Improving Food and Drug Administration–Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval
Cost Effectiveness and Resource Allocation
Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocol
The New England Journal of Medicine
Turning CMS into a health technology assessment organization
JAMA Network Open
Follow-On Indications for Orphan Drugs Related to the Inflation Reduction Act
View All Publications